title: [Cost analysis of the use of botulinum toxin type A in Spain].
abstract: OBJECTIVE
  To estimate treatment costs of blepharospasm, cervical dystonia(CD), upper limb spasticity (ULS) and spasticity in children with cerebral palsy (SCCP) with botulinum neurotoxin type A (BoNT-A) in Spain.
  
  
  METHODS
  Annual BoNT-A treatment costs were calculated (2013 ex-factory price () applying RDL 8/2010 and RDL 9/2011 deductions), based on initial dose (id), average dose (ad) and maximum dose (md) according to Summary of Product Characteristics of Botox® (100U/50U), Dysport®(500U) and Xeomin® (100U) and considering the use of complete vials.In addition, annual treatment costs were calculated considering the useof vials in more than one patient and also patient population annual treatment costs based on diseases' prevalence.
  
  
  RESULTS
  Annual BoNT-A treatment costs per patient were estimated at between 265 and 2,120 with savings from 10% to 55% accordingto the selected BoNT-A. CD and ULS treatment provided the greatest cost per patient. Botox® provided greater savings in ULS (id/ad), CD(id), and in blepharospasm and SCCP (id/ad/md). Dysport® treatment was less costly in CD (md) and ULS (md), while Xeomin® was in CD(ad). Based on the estimated treated population in Spain, the annual treatment costs ranged from 368,392 to 13,958,836 depending on indication, dose and BoNT-A considered.
  
  
  CONCLUSIONS
  The appropriate BoNT-A choice would lead to considerable savings for the National Health System. Botox® would generate lower costs per patient than other BoNT-A products in 9 out of 12 scenarios considered.
authors.affiliation: Pharmacoeconomics & Outcomes Research Iberia, Madrid. fdeandres@porib.com.
authors.forename: F
authors.initials: F
authors.lastname: de Andrés-Nogales
authors.affiliation: Hospital Universitario de La Princesa, Madrid. amorell.hlpr@salud.madrid.org.
authors.forename: A
authors.initials: A
authors.lastname: Morell
authors.affiliation: Allergan, S.A.; Tres Cantos, Madrid.. Aracil_Javier@Allergan.com.
authors.forename: J
authors.initials: J
authors.lastname: Aracil
authors.affiliation: Pharmacoeconomics & Outcomes Research Iberia, Madrid. ctorres@porib.com.
authors.forename: C
authors.initials: C
authors.lastname: Torres
authors.affiliation: Pharmacoeconomics & Outcomes Research Iberia, Madrid. ioyaguez@porib.com.
authors.forename: I
authors.initials: I
authors.lastname: Oyagüez
authors.affiliation: Pharmacoeconomics & Outcomes Research Iberia, Madrid. ma_casado@porib.com.
authors.forename: M A
authors.initials: MA
authors.lastname: Casado
mesh_terms: D000328:Adult; D019274:Botulinum Toxins, Type A / Q000191:economics*; D002648:Child; D016527:Drug Costs / Q000706:statistics & numerical data*; D004363:Drug Utilization; D006801:Humans; D009465:Neuromuscular Agents / Q000191:economics*; D013030:Spain; D013035:Spasm / Q000188:drug therapy / Q000191:economics
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A